Fenretinide: Additional Phase IIb data

Additional data from a 24-month, double-blind Phase IIb trial in 246 patients showed that 100 and 300 mg once-daily oral fenretinide led to median GA lesion growth rates of 12.2% and 11.4%, respectively, vs. 14.5% for placebo at 6 months. At 12 months, patients receiving low- or high-dose fenretinide had median GA lesion growth rates of 26.3% and 21.4%, respectively, vs. 23.7% for placebo. Interim 18-month data reported last year showed that high-dose fenretinide had a median GA lesion growth rate of 22.7% vs. 41.6% for placebo (see BioCentury, April 20, 2009). Low-dose fenretinide led to a median growth rate of 43% at 18 months. Full analysis of all lesion size measurements is ongoing. ...